Aelis Farma Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Aelis Farma ha un patrimonio netto totale di €9.9M e un debito totale di €3.9M, che porta il suo rapporto debito/patrimonio netto a 39.4%. Le sue attività totali e le sue passività totali sono rispettivamente €20.5M e €10.5M.

Informazioni chiave

39.4%

Rapporto debito/patrimonio netto

€3.92m

Debito

Indice di copertura degli interessi	n/a
Contanti	€12.59m
Patrimonio netto	€9.94m
Totale passività	€10.53m
Totale attività	€20.47m

Aggiornamenti recenti sulla salute finanziaria

Nessun aggiornamento

Recent updates

Take Care Before Jumping Onto Aelis Farma SA (EPA:AELIS) Even Though It's 29% Cheaper

Oct 21

Aelis Farma SA's (EPA:AELIS) 49% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Sep 06

Some Confidence Is Lacking In Aelis Farma SA (EPA:AELIS) As Shares Slide 49%

Sep 06

Analisi della posizione finanziaria

Passività a breve termine: Le attività a breve termine ( €18.8M ) di AELIS superano le sue passività a breve termine ( €6.3M ).

Passività a lungo termine: Le attività a breve termine di AELIS ( €18.8M ) superano le sue passività a lungo termine ( €4.2M ).

Storia e analisi del rapporto debito/patrimonio netto

Livello di debito: AELIS ha più liquidità del suo debito totale.

Riduzione del debito: Il rapporto debito/patrimonio netto di AELIS si è ridotto da 169.1% a 39.4% negli ultimi 5 anni.

Bilancio

Analisi della pista di contanti

Per le società che in passato sono state mediamente in perdita, valutiamo se hanno almeno un anno di liquidità.

Pista di liquidità stabile: AELIS ha una liquidità sufficiente per 11 mesi in base all'ultimo reportfree cash flow, ma da allora ha raccolto ulteriori capitali.

Previsione Cash Runway: Si prevede che AELIS disponga di liquidità sufficiente per 11 mesi in base al flusso di cassa libero estimates, ma da allora ha raccolto capitale aggiuntivo.

Aelis Farma Salute del bilancio

Salute finanziaria criteri di controllo 6/6

Informazioni chiave

Aggiornamenti recenti sulla salute finanziaria

Recent updates

Price target decreased by 39% to €9.10

Aelis Farma Announces the Positive Results of Its Clinical Phase 1/2 Study with AEF0217 in Young Adults with Down Syndrome

Take Care Before Jumping Onto Aelis Farma SA (EPA:AELIS) Even Though It's 29% Cheaper

First half 2024 earnings released: €0.27 loss per share (vs €0.13 loss in 1H 2023)

Aelis Farma SA's (EPA:AELIS) 49% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Some Confidence Is Lacking In Aelis Farma SA (EPA:AELIS) As Shares Slide 49%

New major risk - Share price stability

Price target decreased by 27% to €15.00

Aelis Farma Announces the Results of Its Clinical Phase 2B Study with AEF0117, Among Participants with Cannabis Use Disorder (CUD)

Aelis Farma SA Announces the Last Patient, Last Visit in its Clinical Phase 2b Trial with AEF0117 for the Treatment of Cannabis Use Disorder

Full year 2023 earnings released

Aelis Farma SA, Annual General Meeting, Jun 04, 2024

Aelis Farma Announces the Appointment of Arsène Guekam as Chief Corporate Development Officer

Aelis Farma Announces Completion of Patient Randomization for Phase 2B Study with Aef0117 for the Treatment of Cannabis Addiction

Aelis Farma Announces Positive Results of Non-Clinical Studies Required by Regulatory Agencies to Enter Its First Cb1-SSI, AEF0117, in Phase 3 Clinical Trial for the Treatment of Cannabis Use Disorder

New minor risk - Shareholder dilution

First half 2023 earnings released

Aelis Farma Receives a Positive Recommendation From the DSMB to Continue, With No Modification to the Protocol, the Phase 2b Clinical Study With AEF0117 in Cannabis Addiction

Consensus EPS estimates upgraded to €1.36 loss

Aelis Farma Announces the Presentation of New Preclinical Data on its Drug Candidate AEF0217 at the 2nd European Conference on Phelan-McDermid Syndrome

Full year 2022 earnings released

Aelis Farma SA, Annual General Meeting, May 24, 2023

Aelis Farma S.A Announces the Recruitment of the First Patient for the Phase 1/2 Clinical Trial of Its Drug Candidate AEF0217 for the Treatment of Cognitive Disorders in Down Syndrome

High number of new directors

Aelis Farma Announces Positive Results from Its Safety Trials in Healthy Volunteers and the Authorization to Start the First Trial in People with Down Syndrome with AEF0217

First half 2022 earnings released

Aelis Farma S.A. Announces the Inclusion of the 1st Patient in A Phase 2B Study of AEF0117 for the Treatment of Cannabis Use Disorder

High number of new directors

Full year 2021 earnings released

Analisi della posizione finanziaria

Storia e analisi del rapporto debito/patrimonio netto

Bilancio

Analisi della pista di contanti

Scoprire le aziende sane